Long-Term Valuation of Oral Mavacoxib in Osteoarthrosic
Dogs Using Force Platform Analysis
J.M. Vilar*, M. Morales, A. Santana, M. Batista,
F. Miró1 and G. Spinella2
Department of Animal
Pathology, Faculty of Veterinary Medicine, University of Las Palmas
de Gran Canaria, Trasmontaña S/N, Arucas. 35413. Las Palmas, Spain;
1Department of Compared Anatomy and Pathology, Veterinary
Faculty, University of Córdoba, Campus de Rabanales, Ctra. Madrid-Cádiz
Km 396 A, Córdoba,
Spain; 2Department
of Health Sciences, University Magna Graecia of
Catanzaro, 88100 Germaneto (CZ),
Italy *Corresponding author:
jvilar@dpat.ulpgc.es
Abstract
The aim of this study
was to assess the efficacy of mavacoxib, a cox-2 inhibitor, to improve the peak
vertical force (PVF) and vertical impulse (VI) of lame client-owned dogs with
severe coxofemoral osteoarthrosis (OA) by using a force platform. A group of ten canarian presa dogs with lameness and pain for a
severe osteoarthrosis due to hip dysplasia were used for this study. Five
additional sound dogs of the same breed were used as control groups. A single
force platform used to register vertical forces was mounted in a 7 m runway.
Mean (± SD) values for speed of dogs were 1.6±0.5 m/s. Data corresponding with 5
valid trials were recorded at walk at day 0, 7, 60 and 180 after starting
treatment procedure. The dosing regimen consisted of a loading oral dose of 2
mg⁄ kg to be repeated after 14 days, thereafter the dosing interval was 1 month.
OA dogs showed a significant improvement of PVF after two months of about 7% bm
in the force exerted by diseased limbs and a significant VI improvement after
two months of about 1.6% bm in the VI exerted by diseased limbs. This study
clearly showed that dogs treated with mavacoxib increased PVF over time, as soon
as seven days after medical therapy, demonstrating a high potential for clinical
use in the treatment of lameness associated with OA of hip joint.
Key words:
Dog,
Force platform, Lameness,
Mavacoxib, Osteoarthrosis